Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL217662 | 0.85 | CYP3A4 (0.34) | PDE2AIDO1CES2CTSSCTSK | |
| Trimethylammonium SCHEMBL219375 | 0.83 | CES2 (0.38) | PDE2AIDO1CES2MAPTRAPGEF4 | |
| SCHEMBL41567 | 0.82 | CES2 (0.44) | PDE2AIDO1CES2CYP3A4TSHR | |
| SCHEMBL134606 | 0.82 | CYP3A4 (0.35) | PDE2AIDO1CTSSCTSKCYP3A4 | |
| SCHEMBL29853969 | 0.82 | PDE2A (0.36) | PDE2AIDO1CES2CTSSCTSK | |
| SCHEMBL30509222 | 0.81 | CES2 (0.39) | PDE2AIDO1CES2TSHRMAPT | |
| SCHEMBL5460964 | 0.80 | CES2 (0.42) | PDE2AIDO1CES2CYP3A4TSHR | |
| SCHEMBL6866090 | 0.80 | CES2 (0.42) | PDE2AIDO1CES2CYP3A4TSHR | |
| SCHEMBL2451170 | 0.80 | CES2 (0.42) | PDE2AIDO1CES2CYP3A4TSHR | |
| SCHEMBL3464534 | 0.80 | CES2 (0.42) | PDE2AIDO1CES2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 901 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114867758-B | Metallocene and method thereof | 埃克森美孚化学专利公司 | 2025-04-08 | — | — | CN | claimed |
| CN-113614123-B | Transition metal bis (phenoxide) complexes and their use as olefin polymerization catalysts | 埃克森美孚化学专利公司 | 2024-01-23 | — | — | CN | claimed |
| US-11760814-B2 | 1,5 diazabicyclooctane ligand systems and methods therewith | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2023-09-19 | — | — | US | claimed |
| EP-4222180-A1 | BIS(HETEROCYCLIC-OLATE) LEWIS BASE CATALYSTS AND METHODS THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2023-08-09 | — | — | EP | claimed |
| CN-116490528-A | Polymer compositions containing cyclics obtained using transition metal bis (phenoxide) catalyst complexes and process for their preparation | 埃克森美孚化学专利公司 | 2023-07-25 | — | — | CN | claimed |
| EP-4196507-A1 | CYCLIC CONTAINING POLYMER COMPOSITIONS OBTAINED USING TRANSITION METAL BIS(PHENOLATE) CATALYST COMPLEXES AND PROCESS FOR PRODUCTION THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2023-06-21 | — | — | EP | claimed |
| CN-113423744-B | Lewis base catalyst and method thereof | 埃克森美孚化学专利公司 | 2023-05-05 | — | — | CN | claimed |
| CN-113423742-B | Bis (arylphenoxide) lewis base catalysts and methods thereof | 埃克森美孚化学专利公司 | 2023-05-05 | — | — | CN | claimed |
| EP-4103629-A1 | POLYETHYLENE COMPOSITIONS OBTAINED USING TRANSITION METAL BIS(PHENOLATE) CATALYST COMPLEXES AND HOMOGENEOUS PROCESS FOR PRODUCTION THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2022-12-21 | — | — | EP | claimed |
| EP-4103628-A1 | PROPYLENE POLYMERS OBTAINED USING TRANSITION METAL BIS(PHENOLATE) CATALYST COMPLEXES AND HOMOGENEOUS PROCESS FOR PRODUCTION THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2022-12-21 | — | — | EP | claimed |
| US-20040266961-A1 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. | 2004-12-30 | — | — | US | claimed |
| WO-2004106390-A2 | POLYMERIZATION AND OLIGOMERIZATION CATALYST WITH TRIDENTATE OR TETRADENTATE LIGAND | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-12-09 | — | — | WO | claimed |
| WO-2004026923-A9 | SUPERCRITICAL POLYMERIZATION PROCESS AND POLYMERS PRODUCED THEREFROM | EXXONMOBIL CHEM PATENTS INC (US) | 2004-09-10 | — | — | WO | claimed |
| US-20040122191-A1 | Supercritical polymerization process and polymers produced therefrom | EXXONMOBIL CHEMICAL PATENTS INC | 2004-06-24 | — | — | US | claimed |
| WO-2004026923-A2 | SUPERCRITICAL POLYMERIZATION PROCESS AND POLYMERS PRODUCED THEREFROM | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-04-01 | — | — | WO | claimed |
| EP-0792317-B1 | LIQUID PVC STABILIZERS AND LUBRICANTS | CROMPTON CORP (US) | 2004-02-18 | — | — | EP | claimed |
| WO-2004007509-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-01-22 | — | — | WO | claimed |
| EP-0418044-B2 | Metal complex compounds, process for preparation and method of use | DOW CHEMICAL CO (US) | 2003-08-20 | — | — | EP | claimed |
| EP-0418044-B1 | Metal complex compounds, process for preparation and method of use | DOW CHEMICAL CO (US) | 1997-09-10 | — | — | EP | claimed |
| EP-0765882-A2 | Metal complex compounds, process for preparation and method of use | THE DOW CHEMICAL COMPANY (US) | 1997-04-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760814-B2 | 1,5 diazabicyclooctane ligand systems and methods therewith | ODC1, DDT, OXGR1 | PDE2A 4203/4885IDO1 145/4885CES2 1107/4885 |
| US-20040266961-A1 | Catalyst composition II | MLX, CBX2, BMX | PDE2A 4778/4885IDO1 652/4885CES2 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.